Paul R. Kirchgraber

Insider Reports History

Entity
Individual
Location
531 South Spring Street, Burlington, NC
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Paul R. Kirchgraber:

Stock Role Class Num Shares Value Price $ Report Date Ownership
LABORATORY CORP OF AMERICA HOLDINGS CEO, Covance Drug Development Common Stock 12.9K $2.84M $219.50 May 19, 2023 Direct
LABORATORY CORP OF AMERICA HOLDINGS CEO, Covance Drug Development Non-qualified Stock Options 0 May 19, 2023 Direct

Insider Reports Filed by Paul R. Kirchgraber

Symbol Company Period Transactions Value $ Form Type Date Filed Role
LH LABORATORY CORP OF AMERICA HOLDINGS May 19, 2023 3 -$148K 4 May 23, 2023 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Mar 30, 2023 2 -$648K 4 Apr 3, 2023 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Feb 21, 2023 3 -$1.46M 4 Feb 23, 2023 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Feb 11, 2023 3 -$35.2K 4 Feb 14, 2023 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Feb 7, 2023 2 $0 4 Feb 9, 2023 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Feb 4, 2023 3 -$40.1K 4 Feb 7, 2023 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Feb 2, 2023 3 -$36K 4 Feb 6, 2023 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Nov 1, 2022 3 -$199K 4 Nov 3, 2022 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Mar 27, 2022 2 -$456K 4 Mar 29, 2022 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Feb 11, 2022 5 -$29.4K 4 Feb 15, 2022 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Feb 4, 2022 3 -$45.8K 4 Feb 8, 2022 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Feb 2, 2022 3 -$39.3K 4 Feb 4, 2022 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS Nov 1, 2021 3 -$259K 4 Nov 3, 2021 CEO, Covance Drug Development
LH LABORATORY CORP OF AMERICA HOLDINGS May 6, 2021 1 -$691K 4 May 10, 2021 CEO, Covance Drug Development